Omalizumab is a recombinant, humanized monoclonal antibody that targets immunoglobulin E (IgE), playing a key role in the treatment of allergic diseases such as moderate-to-severe asthma and chronic idiopathic urticaria. By binding to circulating IgE and preventing its interaction with high-affinity IgE receptors on mast cells and basophils, omalizumab reduces the release of proinflammatory mediators that contribute to the allergic cascade. This inhibition diminishes the activation and recruitment of inflammatory cells, including B-lymphocytes, T-lymphocytes, eosinophils, and fibroblasts, thereby modulating airway inflammation and remodeling.
In research and clinical settings, omalizumab serves as both a therapeutic and a monitoring target in immunology and allergy-focused studies. It is particularly valuable in therapeutic drug monitoring (TDM) applications, where maintaining optimal serum concentrations can improve clinical outcomes and reduce adverse effects. TDM of omalizumab allows clinicians to assess treatment efficacy, detect patient noncompliance, and monitor for the development of anti-drug antibodies (ADAs) that may impact drug pharmacokinetics and safety.
Omalizumab’s mechanism of action and its immunogenic potential make it a critical biomarker for understanding immune modulation in allergic diseases. Due to its recombinant protein structure and potential to elicit ADAs, omalizumab also represents a model biologic for biosimilar development and immunogenicity profiling. Its utility in precision medicine continues to expand, supporting individualized dosing regimens and contributing to broader biologic drug safety evaluations.
This product is manufactured in Turkey by Matriks Biotek.